December 14, 2000


BLA 99-0786 Campath (alemtuzumab) - indicated for the treatment of patients with chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy

Millenium and ILEX Partners LP


The statements contained in this document are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Overview of CLL: Need for New Therapeutic Options; presentation of Clinical Data, Micahel J Keating, MB, BS, MD, Anderson Cancer Center, Lee R Brettman, MD, Millenium Pharmaceuticals   ppt   html

FDA Presentation, Genevieve Schechter, MD   ppt   html

Single Patient Use of Non-approved Oncology Drugs and Biologics

Introduction, Grant Williams, MD, FDA   ppt   html

Perspective from Industry

Robert Spiegel, MD, Schering-Plough Research Institute   ppt   html

Gerard T Kennealey, MD, AstraZeneca Pharmaceuticals   ppt   html